Global contract development and manufacturing organisation (CDMO), Recipharm, has announced investment into a new facility in Uttarakhand, India which will see its fill finish capacity increase to 1 billion sterile units per year.
The facility will be constructed on a greenfield site near Dehradun in Uttarakhand and is a joint project between Recipharm and the Sobti family.
The new site, which is designed for approval to supply the EU and US is now ready to begin production following approval from the local authorities. It will be delivering ampoules, vials filled with liquid and powder, lyophilised vials, dental cartridges, and pre-filled syringes.
Marc Funk, CEO of Recipharm said: “This is a great milestone for our ongoing partnership with the Sobti family. From the new facility we’ll be able to provide customers with invaluable access to high quality sterile fill & finish capacity, which is in huge demand globally. A lot of hard work has gone in to ensuring the success of this project and we’re delighted to see it come to fruition.”
The new facility is the latest development in Recipharm’s partnership with the Sobti family which began in 2019 when Recipharm invested in Nichepharm.
Dr Chetan Sobti and Nitin Sobti, co-founders of Nichepharm said: “This partnership represents a real opportunity to take Nichepharm to the next level. The Sobti family is very pleased to be entering in the next stage of this partnership with Recipharm which will bring it access to new technologies, best in class account management and global standards of GMP compliance.”
The next step for the project will be to obtain authorisation from the European authorities.
The facility will allow Recipharm to further increase its offering in sterile fill & finish service as it complements its three other sterile filling capabilities in France, Germany and Italy.
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.